<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942457</url>
  </required_header>
  <id_info>
    <org_study_id>KiWuA</org_study_id>
    <nct_id>NCT04942457</nct_id>
  </id_info>
  <brief_title>Efficacy of Fasting on Hormone Dosage in Fertility Treatment</brief_title>
  <acronym>KiWuA</acronym>
  <official_title>Effects of Fasting on Hormone Dosage in Fertility Treatment in Women With Ovulation Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karl and Veronica Carstens Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study investigates fasting as a potential supportive therapy in infertility&#xD;
      treatment for women undergoing ovulation induction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 3-arm, randomized, controlled exploratory clinical trial aims to explore fasting as a&#xD;
      novel supportive treatment in infertility, especially focussing on potential dose reduction&#xD;
      during ovulation induction. The participants will be randomized in three groups: fasting,&#xD;
      weight-loss and counselling on supplements. All groups will be trained and accompanied by&#xD;
      medical experts and dieticians. In addition, qualitative interviews will be conducted&#xD;
      including individual and focus group interviews with a subgroup of participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are 3 parallel groups following different nutritional regimes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>It is not possible to mask a fasting intervention for the participant or the study personel. Therefore only outcome assessors are masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative drug dose for ovulation induction</measure>
    <time_frame>baseline and until end of treatment for ovulation induction (2-6 months)</time_frame>
    <description>Cumulative dosage of hormonal therapy for each assisted cycle of ovulation induction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative interview analysis of fasting experience</measure>
    <time_frame>in time frame of 24 weeks after fasting intervention</time_frame>
    <description>individual and focus group interviews</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregancy rate</measure>
    <time_frame>at baseline, after one month, at end of ovulation induction treatment (2-6 months) and 12 months after baseline</time_frame>
    <description>pregnancy rate of the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication rates in pregnancy</measure>
    <time_frame>12 months after baseline</time_frame>
    <description>complication rates monitored by the gynaecologist, if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal status</measure>
    <time_frame>at the beginning and end of each ovulatory cycle, for up to 12 months</time_frame>
    <description>FSH, LH, Estrogen, Progesteron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>baseline and at end of ovulation induction treatment (2-6 months), for up to 12 months</time_frame>
    <description>serum parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO-5</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diet</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>questionnaire to examine dietary behaviour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mindfulness</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>MAAS-questionnaire, validated questionnaire to examine mindfulness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anxiety and depression</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>HADS-questionnaire, validated questionnaire to examine anxiety and depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>current mood</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>ASTS-questionnaire, validated questionnaire to examine current mood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>experienced stress</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>Cohen-stress scale, validated questionnaire to examine experienced stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical fitness</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>questionnaire to examine physical fitness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of relationship</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>questionnaire to examine the relationship between the two partners desiring to have a child</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychological stress caused by the unfulfilled desire to have children</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>questionnaire to examine the psychological stress caused by the unfulfilled desire to have children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gratitude</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>validated questionnaire to examine gratitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-efficacy</measure>
    <time_frame>at baseline, after fasting (1-3 weeks), after one month, at end of ovulation induction treatment (2-6 months)and 12 months after baseline</time_frame>
    <description>ASKU, validated questionnaire to examine self-efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal ultrasound after liver wrap</measure>
    <time_frame>before, during and after the fasting intervention</time_frame>
    <description>sonography in a subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of ovulations</measure>
    <time_frame>at baseline, after one month, at end of ovulation induction treatment (2-6 months) and 12 months after baseline</time_frame>
    <description>ovulation visible in sonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function parameters</measure>
    <time_frame>at baseline, after one month, at end of ovulation induction treatment (2-6 months), after 12 months</time_frame>
    <description>serum liver enzymes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pyruvate in culture medium of oocytes, if applicable (in case of IVF/ICSI)</measure>
    <time_frame>after in vitro fertilisation, if applicable during study period of one year</time_frame>
    <description>chemical composition of culture medium (pyruvate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose in culture medium of oocytes, if applicable (in case of IVF/ICSI)</measure>
    <time_frame>after in vitro fertilisation, if applicable during study period of one year</time_frame>
    <description>chemical composition of culture medium (glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate in culture medium of oocytes, if applicable (in case of IVF/ICSI)</measure>
    <time_frame>after in vitro fertilisation, if applicable during study period of one year</time_frame>
    <description>chemical composition of culture medium (lactate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitoring</measure>
    <time_frame>14 days after baseline</time_frame>
    <description>Continuous Glucose Monitoring via CGM-Device in subgroup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketone bodies in breath</measure>
    <time_frame>up to 4 days before, during and up to 7 days after fasting intervention</time_frame>
    <description>Breath acetone, in subgroup</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sub Fertility, Female</condition>
  <condition>Fertility Disorders</condition>
  <condition>Cycle Disorders Menstrual</condition>
  <condition>Ovulation Disorder</condition>
  <condition>Ovulation Absent</condition>
  <condition>Ovulation Delayed</condition>
  <condition>Ovulation; Failure or Lack of</condition>
  <condition>Sub-fertility</condition>
  <arm_group>
    <arm_group_label>Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be councelled and accompanied to follow a prolonged fasting regime of 7-10 days in an outpatient setting under medical supervision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Weight-loss</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 x dietary counselling for weight-loss</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Counselling on nutrients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 x dietary counselling on important nutrients while trying to conceive, usual diet should be maintained</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fasting</intervention_name>
    <description>Prolonged fasting for 7-10 days (caloric intake &lt;500 kcal in liquid form)</description>
    <arm_group_label>Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight-loss</intervention_name>
    <description>8 x dietary counselling for weight-loss</description>
    <arm_group_label>Weight-loss</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counselling on nutrients</intervention_name>
    <description>1 x dietary counselling on important nutrients while trying to conceive, usual diet should be maintained</description>
    <arm_group_label>Counselling on nutrients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 25 to 38 years&#xD;
&#xD;
          -  Unfulfilled desire to have children &gt;1 year&#xD;
&#xD;
          -  declaration of consent&#xD;
&#xD;
          -  25 kg/m² ≤ BMI ≤ 35 kg/m²&#xD;
&#xD;
          -  Successful treatment for ovulation induction in cooperating infertily treatment center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Language barriers&#xD;
&#xD;
          -  Previously known serious mental illness or cognitive impairment&#xD;
&#xD;
          -  Patients with anatomical/organic damage and proven uterine abnormalities&#xD;
&#xD;
          -  Eating disorders in the medical history&#xD;
&#xD;
          -  Serious previous internal diseases&#xD;
&#xD;
          -  Lack of internet access&#xD;
&#xD;
          -  No consent to randomisation&#xD;
&#xD;
          -  Participation in other studies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>biological female sex</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Michalsen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Liebscher, Dr.</last_name>
    <phone>03080505770</phone>
    <email>daniela.liebscher@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Kessler, PD Dr.</last_name>
    <phone>03080505691</phone>
    <email>christian.kessler@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hochschulambulanz für Naturheilkunde der Charité-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela A. Liebscher, Dr. med.</last_name>
      <phone>+493080505770</phone>
      <email>daniela.liebscher@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Michalsen</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>fasting</keyword>
  <keyword>natural therapies</keyword>
  <keyword>caloric restriction</keyword>
  <keyword>lifestyle modification</keyword>
  <keyword>dietary restriction</keyword>
  <keyword>dietary intervention</keyword>
  <keyword>prolonged fasting</keyword>
  <keyword>weight loss</keyword>
  <keyword>complementary medicine</keyword>
  <keyword>integrative medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Anovulation</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Menstruation Disturbances</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>after the end of the study for 5 years</ipd_time_frame>
    <ipd_access_criteria>on demand.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

